Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 21 Results

Title
Intervention Indication Therapeutic Area Year Actions
Durvalumab (Imfinzi) for locally advanced or metastatic urothelial bladder cancer – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Bladder cancer Urological Cancer 2017 View  |  Download
Durvalumab (Imfinzi) monotherapy for advanced or metastatic non-small cell lung cancer (EGFR and ALK wild type) – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
Durvalumab add-on therapy for previously untreated locally advanced cervical cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Cervical cancer Female Reproductive Cancer 2022 View  |  Download
Durvalumab and bevacizumab in addition to transarterial chemoembolisation for locoregional hepatocellular carcinoma Bevacizumab (Avastin; R 435; RG 405; RG 435) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Transarterial Chemoembolisation (TACE) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2021 View  |  Download
Durvalumab for advanced, EGFR/ALK wild-type, high PD-L1 expression, non-small cell lung cancer- first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Durvalumab for limited stage small-cell lung cancer after
1 therapy
Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2022 View  |  Download
Durvalumab for previously untreated,hepatocellular carcinoma Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2021 View  |  Download
Durvalumab for recurrent or metastatic squamous cell carcinoma of the head and neck – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Head and neck cancer Head and Neck Cancer 2019 View  |  Download
Durvalumab in addition to chemotherapy for metastatic non-small-cell lung cancer - first line Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2019 View  |  Download
Durvalumab in addition to gemcitabine and cisplatin for advanced biliary tract cancer – first line Cisplatin (Platinol) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Gemcitabine (Gemzar; gemcitabine hydrochloride) Biliary tract cancer Gastrointestinal Cancer 2021 View  |  Download
1 2 3
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications